- GSK said in February Pfizer would keep Haleon stake
- Haleon expected to list in London on July 18
- GSK rebuffed Unilever’s 50 billion pound offer for Haleon
LONDON, June 1 (Reuters) – Pfizer (PFE.N) plans to sell its 32% stake in Haleon, its consumer health venture with British drugmaker GSK (GSK.L), after the business lists as an independent company in July, GSK said on Wednesday.
GSK is spinning off Haleon, which makes Sensodyne toothpaste and Advil painkillers, so it can focus on vaccines and prescription drugs. GSK rejected a 50 billion pound ($63 billion) offer for Haleon last year, saying it undervalued the firm.
Pfizer has previously indicated it wanted to sell its stake in Haleon but GSK, which owns 68% of the world’s biggest consumer health business, said in February that the U.S. drugmaker would keep its stake after a flotation.
Register now for FREE unlimited access to Reuters.com
Register
A Pfizer spokesperson said on Wednesday…
